Analytical Data
-
基因名
NANP
- Application
-
别名
NANP；Homeobox Protein NANOGP8
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q8TBE9
-
表达区间
1-248aa
-
氨基酸序列
MRGSHHHHHHGMASMTGGQQMGRDLYDDDDKDRWGS MGLSRVRAVFFDLDNTLIDTAGASRRGMLEVIKLLQSKYHYKEEAEIICD KVQVKLSKECFHPYNTCITDLRTSHWEEAIQETKGGAANRKLAEECYFLW KSTRLQHMTLAEDVKAMLTELRKEVRLLLLTNGDRQTQREKIEACACQSY FDAVVVGGEQREEKPAPSIFYYCCNLLGVQPGDCVMVGDTLETDIQGGLN AGLKATVWINKNGIVPLKSSPVPHYMVSSVLELPALLQSIDCKVSMST
-
分子量
32 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
NANP, a peptide derived from the circumsporozoite protein of Plasmodium falciparum, has garnered significant attention in malaria vaccine research due to its role in the parasite's lifecycle and its immunogenic potential. The World Health Organization continues to spotlight malaria as a major global health challenge, necessitating the development of effective vaccines to reduce morbidity and mortality associated with this disease. The NANP repeat region is highly conserved and elicits strong immune responses, making it an attractive target for vaccine development. Recent studies have focused on the engineering of NANP as a recombinant protein, aiming to enhance its immunogenicity through various adjuvant strategies and delivery systems. The successful expression of NANP in heterologous systems, along with optimization strategies to improve its stability and efficacy, underscores its potential as a key component in malaria vaccines. As researchers explore the mechanisms by which NANP elicits protective immunity, advancements in its formulation may contribute to the development of a safe and effective malaria vaccine, ultimately paving the way for groundbreaking approaches to malaria prevention and control.
